Page last updated: 2024-09-04

tipifarnib and Exanthema

tipifarnib has been researched along with Exanthema in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J1
Mardiak, J; Moore, M; Palmer, PA; Perez-Ruixo, JJ; Rosenberg, JE; Sahasrabudhe, D; Seigne, JD; Small, EJ; Vaughn, DJ; von der Maase, H1

Trials

2 trial(s) available for tipifarnib and Exanthema

ArticleYear
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome

2005
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Cancer, 2005, May-15, Volume: 103, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Diarrhea; Enzyme Inhibitors; Exanthema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quinolones; Remission Induction; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

2005